Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials.
This study by Suissa et al (Circulation: Cardiovascular Quality and Outcomes– Jan 2017) evaluated the efficacy and safety of pharmacological and behavioral interventions for smoking cessation in patients with cardiovascular disease. The authors performed a systematic review and meta-analysis to pool together the results of 7 trials examining pharmacological interventions, and 17 trials of behavioral interventions, including a total of 7,475 patients.
The results showed that varenicline (Champix) and bupropion (Zyban SR) were associated with greater abstinence from smoking than placebo at 6 and 12 months. The benefits of nicotine replacement therapies and in-hospital behavioral interventions were inconclusive, however telephone therapy and individual counseling both led to better abstinence than usual care procedures.